Three children all suffer from genetic enzyme deficiency that could lead to early death
CBC News Posted: Sep 15, 2015 5:30 AM CT Last Updated: Sep 15, 2015 6:43 AM CT
A family in Saskatoon is waiting and hoping for the solution to a triple heartbreak. Three of the five children suffer from a crippling genetic disease that could kill them.
Muhammad Abdullah, 12, Khadija Amir, 10 and Sara Amir, 8 all have a rare enzyme deficiency called Morquio A Syndrome (also called MPS IV type A).
“Until the age of three to four nobody can judge that there’s anything wrong with them actually,” their father, Muhammad Amir Akhter said. “After that the symptoms appear, and almost every part of the body is affected.”
Without the missing enzyme, cellular waste builds up in the bones, tissues, organs and muscles.
The condition is stunting the children’s growth, twisting their joints, affecting their eyesight and hearing, and making it tough for them to breathe. Two of them use wheelchairs at school.
It’s so rare, it only appears in an estimated one out of every 200,000 to 300,000 children.
Hope placed in costly synthetic enzyme
There is no cure. But a synthetic enzyme called Vimizim could slow or even halt the progression of their disease, and help them live longer.
An advocacy group called the Isaac Foundation said Health Canada approved Vimizim more than a year ago.
Now Akhter and his wife Shazia Amir are waiting to find out if the province will pay the cost, which could be in the hundreds of thousands of dollars each year.
“It’s really hard to wait for the decision,” Akhter said. “You know we are anxiously looking forward to see every day morning, we are looking for any positive response from the government side to get that too, to get started that replacement therapy.”
Health ministry considering compassionate coverage
He said they applied seven months ago. However, Saskatchewan’s Ministry of Health said it only got complete information from the children’s doctor late last month.
It also said the national Common Drug Review made a “Do Not List” recommendation for Vimizim for clinical reasons.
However, the ministry is considering compassionate coverage on a case-by-case basis.
In the case of Akhter’s children, the ministry has sent their requests to an out-of-province specialist for review and advice.
If they are turned down, Akhter said he will consider moving the family to another province that is willing to pay for their treatment. The Isaac Foundation said Ontario and Quebec have reimbursed patients for Vimizim.